The T61 human breast cancer xenograft: An experimental model of estrogen therapy of breast cancer

[1]  R. Clarke,et al.  MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. , 1993, Cancer research.

[2]  N. Brünner,et al.  Effect of endocrine therapy on growth of T61 human breast cancer xenografts is directly correlated to a specific down-regulation of insulin-like growth factor II (IGF-II). , 1993, European journal of cancer.

[3]  H. Rochefort,et al.  Activation of estrogen receptor transfected into a receptor-negative breast cancer cell line decreases the metastatic and invasive potential of the cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[4]  V. Jordan,et al.  Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. , 1992, Journal of the National Cancer Institute.

[5]  V. Jordan.  Overview from the International Conference on Long-Term Tamoxifen Therapy for Breast Cancer. , 1992, Journal of the National Cancer Institute.

[6]  J. Aro.  Cardiovascular and all‐cause mortality in prostatic cancer patients treated with estrogens or orchiectomy as compared to the standard population , 1991, The Prostate.

[7]  D. Yee,et al.  A novel human insulin-like growth factor I messenger RNA is expressed in normal and tumor cells. , 1990, Molecular endocrinology.

[8]  O. Alfthan,et al.  Effects of orchiectomy and polyestradiol phosphate therapy on serum lipoprotein lipids and glucose tolerance in prostatic cancer patients. , 1990, European urology.

[9]  B. V. VON Schoultz,et al.  Estrogen therapy and liver function—metabolic effects of oral and parenteral administration , 1989, The Prostate.

[10]  D. Yee,et al.  Insulin-like growth factor II mRNA expression in human breast cancer. , 1988, Cancer research.

[11]  B. V. VON Schoultz,et al.  Cardiovascular follow‐up of patients with prostatic cancer treated with single‐drug polyestradiol phosphate , 1988, The Prostate.

[12]  H. Rochefort,et al.  Antiestrogens inhibit the mitogenic effect of growth factors on breast cancer cells in the total absence of estrogens. , 1987, Biochemical and biophysical research communications.

[13]  N. Brünner,et al.  Effect of tamoxifen on the receptor-positive T61 and the receptor-negative T60 human breast carcinomas grown in nude mice. , 1985, European journal of cancer & clinical oncology.

[14]  N. Brünner,et al.  Characterization of the T61 human breast carcinoma established in nude mice. , 1985, European journal of cancer & clinical oncology.

[15]  J. Lokich,et al.  Randomized trial of estrogen vs. tamoxifen therapy for advanced breast cancer , 1985, American journal of clinical oncology.

[16]  N. Brünner,et al.  Dose-dependent effect of 17 beta-estradiol determined by growth curves and flow cytometric DNA analysis of a human breast carcinoma (T61) grown in nude mice. , 1985, Experimental cell biology.

[17]  L. Beex,et al.  Tamoxifen versus ethinyl estradiol in the treatment of postmenopausal women with advanced breast cancer. , 1981, Cancer treatment reports.

[18]  J. Ingle,et al.  Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. , 1981, The New England journal of medicine.

[19]  Ostrowski Mj,et al.  Polyestradiol phosphate: a preliminary evaluation of its effect on breast carcinoma. , 1979 .

[20]  A. W. Jackson,et al.  Polyestradiol phosphate: a preliminary evaluation of its effect on breast carcinoma. , 1979, Cancer treatment reports.

[21]  N. Sedransk,et al.  Diethylstilbestrol: recommended dosages for different categories of breast cancer patients. Report of the Cooperative Breast Cancer Group. , 1977 .